The EQ-5D-5L Predicts Treatment Outcomes and Provides Added Value to the R-IPSS in Patients with MDS, CMML or AML Treated within the Austrian Azacitidine Registry - a Prospective Cohort Study By the AGMT Study Group

Lisa Pleyer, S Heibl, C Tinchon, S Vallet, B Petricevic, Michael Leisch, Alexander Egle, TM Senn, T Grochtdreis, Richard Greil, R Stauder

Research output: Contribution to journalpublished Abstract (Journal)peer-review

Original languageEnglish
Publication statusPublished - 2021

Cite this